Skip to main content

Table 1 Health assessment questionnaire and short form-36 physical and mental component summary scores

From: Improved health outcomes with Etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis

Instrument/ ETN + MTX DMARD + MTX P value
 Time on therapy    
HAQ Score Mean Score (% Improvement from Baseline) (N)  
 Baseline 1.37 (0%) (N = 197) 1.41 (0%) (N = 103)  
 Week 16 0.69 (49.4%) (N = 193) 0.87 (38.3%) (N = 100) 0.025*
HAQ Proportion Patients achieving HAQ Score  ≤  0. 5, Proportion (%)  
 Baseline 28/197 (14.2%) 13/103 (12.6%)  
 Week 16 100/193 (51.8%) 39/100 (39.0%) 0.048**
SF-36 Physical Component Summary Scores Mean Score (% Improvement from Baseline) (N)  
 Baseline 30.5 (0%) (N = 193) 30.1 (0%) (N = 100)  
 Week 16 40.4 (31.4%) (N = 189) 37.3 (22.8%) (N = 96) 0.003*
SF-36 Mental Component Summary Scores Mean Score (% Improvement from Baseline) (N)  
 Baseline 42.9 (0%) (N = 193) 42.4 (0%) (N = 100)  
 Week 16 50.2 (17.5%) (N = 189) 47.8 (13.3%) (N = 96) 0.047*
  1. Scores at Baseline and Following 16 Weeks of Therapy in Asia-Pacific Rheumatoid Arthritis Patients Treated With ETN + MTX versus DMARD + MTX (Last Observation Carried Forward Analysis).
  2. DMARD: Disease Modifying Antirheumatic Drug; ETN: etanercept; FACIT-Fatigue: Functional Assessment of Chronic Illness Therapy- Fatigue; HAQ: Health Assessment Questionnaire; MTX: methotrexate; SF-36: Medical Outcomes Short Form-36 Health Survey.
  3. Values have been rounded.
  4. *ANCOVA, considering the factors ‘baseline score + therapy + country’.
  5. **Cochran-Mantel-Haenszel Test.